Nanofiltration of single plasma donations: Feasibility study

Vox Sanguinis

Volumn 84, Issue 2, 2003, Pages 111-119

  Burnouf, T ^a   Radosevich, M ^a   El Ekiaby, M ^c   Satoh, S ^b   Sato, T ^b   Amin, S N ^d   Savidge, G F ^e   Goubran, H A ^d  

^a HUMAN PROTEIN PROCESS SCIENCES   (France)

^b ASAHI KASEI CORPORATION   (Japan)

^c Shabrawishi Hospital Blood Bank   (Egypt)

^d CAIRO UNIVERSITY   (Egypt)

^e ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Nanofiltration; Plasma; Proteins; Transfusion; TSE; Virus

Indexed keywords

BLOOD CLOTTING FACTOR; DNA; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROTEIN; RNA;

APHERESIS; ARTICLE; BLOOD DONOR; CLINICAL ARTICLE; DNA DETERMINATION; ELECTROPHORESIS; FEASIBILITY STUDY; FLOW RATE; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; NANOFILTRATION; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; RNA ANALYSIS;

BLOOD DONORS; DNA, VIRAL; FEASIBILITY STUDIES; FILTRATION; HEPACIVIRUS; HUMANS; LEUKOCYTES; MEMBRANES, ARTIFICIAL; PLASMA; PLASMAPHERESIS; POLYMERASE CHAIN REACTION; POROSITY; SAFETY;

EID: 0038666249     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.2003.00265.x     Document Type: Article

References (45)

1. Manabe SI, Kamata Y, Iijima H, Kamide K: Some morphological characteristics of porous polymeric membranes prepared by 'micro-phase' separation method. Polymer J 1987; 19:391-404
2. Sekiguchi S, Ito K, Kobayashi M, Ikeda H, Manabe S, Tsurumi T, Ishikawa G, Satani M, Yamaguchi K: Possibility of hepatitis B virus (HBV) removal from human plasma using regenerated cellulose hollow fiber (BMM). Membrane 1989; 14:253-261
3. Manabe S, Tsurumi T, Ishikawa G, Satani M, Tamashiki T, Hamamoto Y, Yamaguchi K, Kobayashi S, Yamamoto N: Mechanism of human immunodeficiency virus (HIV) removal by regenerated cellulose hollow fiber (BMM). Membrane 1989; 14:77-83
4. Manabe S: Removal of virus through novel membrane filtration method. Dev Biol Stand 1996; 88:81-90
5. Burnouf-Radosevich M, Appourchaux P, Huart JJ, Burnouf T: Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates. Vox Sang 1994; 67:132-138
6. Burnouf T, Radosevich M: Nanofiltration of plasma biopharmaceutical products. Haemophilia 2003; 9:24-37
7. Burnouf T, Radosevich M: Reducing the risk of infection from plasma products; specific preventative strategies. Blood Rev 2000; 14:94-110
8. Tateishi J, Kitamoto T, Ishikawa G, Manabe S: Removal of causative agent of Creutzfeldt-Jakob disease (CJD) through membrane filtration method. Membrane 1993; 18:357-362
9. Tateishi J, Kitamoto T, Mohri S, Satoh S, Sato T, Shepherd A, Macnaughton MR: Scrapie removal using Planova® virus removal filters. Biologicals 2001; 29:17-25
10. Clauss A: Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens. Acta Haematol 1957; 17:237
11. European Pharmacopoeia 4: Human Plasma for Fractionation. Monograph 01/2002: 0853. Strasbourg: Council of Europe. 2002;1928-1929
12. Turecek PL, Siekmann J, Schwarz HP: Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor. Semin Thromb Hemost 2002; 28:149-160
13. Horowitz MS, Pehta JC: SD Plasma in TTP and coagulation factor deficiencies for which no concentrates are available. Vox Sang 1998; 74:231-235
14. Cardigan R, Sutherland J, Garwood M, Krailadsiri P, Seghatchian J, Beard M, Beckman N, Williamson. LM: The effect of leucocyte depletion on the quality of fresh-frozen plasma. Br J Haematol 2001; 114:233-240
15. Cadroy Y, Pierrejean D, Fontan B, Sie P, Boneu B: Influence of aging on the activity of the hemostatic system: prothrombin fragment 1 + 2, thrombin-antithrombin III complexes and Ddimers in 80 healthy subjects with age ranging from 20 to 94 years. Nouv Rev Fr Hematol 1992; 34:43-46
16. Goudemand J, Peynet J, Chambost H, Negrier C, Briquel ME, Claeyssens S, Derlon-Borel A, Guerois C, Caron C, Scherrmann JM, Debray M, Bridey F: A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate. Thromb Haemost 1998; 80:919-924
17. National Institutes of Health: Consensus Development Conference Statement Fresh frozen plasma: indications and risks. National Institute of Health Consensus. Transfus Med Rev 1987; 1:201-204
18. Wieding JU, Vehmeyer K, Dittman J, Hiddemann W, Kohler M, Lanzer G: Contamination of fresh-frozen plasma with viable white cells and proliferative stem cells. Transfusion 1994; 34:185-186
19. Nielsen HJ, Reimert C, Pedersen AN, Dybkjoer E, Brunner N, Alsbjorn B, Skov PS: Leucocyte-derived bioactive substances in fresh frozen plasma. Br J Anaesth 1997; 78:548-552
20. Brand A: Immunological aspects of blood transfusions. Blood Rev 2000; 14:130-144
21. Hiruma K, Okuyama Y: Effect of leucocyte reduction on the potential alloimmunogenicity of leucocytes in fresh-frozen plasma products. Vox Sang 2001; 80:51-56
22. Turner ML, Ironside JW: New-variant Creutzfeldt-Jakob disease: the risk of transmission by blood transfusion. Blood Rev 1998; 12:255-268
23. Brown P, Cervenakova L, McShane LM, Auto Crber P, Rubeinstein R, Drohan W: Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999; 39: 1169-1178
24. Brown P, Rohwer RG, Dunstan BC, MacAuley C, Gajdusek DC, Drohan WN: The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 1998; 38:810-816
25. Barclay GR, Hope J, Birkett CR, Turner ML.: Distribution of cell-associated prion protein in normal adult blood determined by flow cytometry. Br J Haematol 1999; 107:804-814
26. Bessos H, Drummonds O, Prowse C, Turner M, MacGregor I: The release of prion protein from platelets during storage of apheresis platelets. Transfusion 2001; 41:61-66
27. Prowse CV, Hornsey VS, Drummond O, MacGregor IR, Pepper DS, Barclay GR, Bethel H, Walker B, Barnard G, Kirby L, Hope J: Preliminary assessment of whole-blood, red-cell and plateletleucodepleting filters for possible induction of prion release by leucocyte fragmentation during room temperature processing. Br J Haematol 1999; 106:240-247
28. Lee DC, Stenland CJ, Miller JL, Cai K, Ford EK, Gilligan K J KJ, Hartwell RC, Terry JC, Rubenstein R, Foumel M, Petteway SR Jr: A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy during the purification of plasma proteins. Transfusion 2001; 41:433-436
29. Foster PR, Welch AG, McLean C, Griffin BD, Hardy JC, Bartley A, MacDonald S, Bailey AC: Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma proteins. Vox Sang 2000; 78:86-95
30. Troccoli NM, McIver J, Losikoff A, Poiley J: Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration. Biologicals 1998; 26:321-329
31. Takeda Y, Wakisaka A, Noguchi K, Murozuka T, Katsubayashi Y, Matsumoto S, Tomono T, Nishioka K: Receptor-mediated haemagglutination screening and reduction in the viral load of parvovirus B 19 DNA in immunopurified Factor VIII concentrate (Cross Eight®). Vox Sang 2001; 81:266-268
32. Lambrecht B, Mohr H, Knüver-Hopf J, Schmitt H: Inactivation of viruses in human fresh frozen plasma by phenothiacine dyes in combination with visible light. Vox Sang 1991; 60:207-213
33. Horowitz B, Lazo A, Grossberg H, Page G, Lippin A, Swan G: Virus inactivation by solvent-detergent treatment and the manufacture of SD-plasma. Vox Sang 1998; 74:203-206
34. Burnouf-Radosevich M, Burnouf T, Huart JJ: A pasteurized therapeutic plasma. Infusionstherapie 1992; 19:91-94
35. Hart H, Reid K, Hart W: Inactivation of viruses during ultraviolet light treatment of human intravenous immunoglobulin and albumin. Vox Sang 1993; 64:82-88
36. Highsmith FA, Caple M, Walthall B, Shanbrom E, Drohan W: Viral inactivation of vesicular stomatitis virus in normal human serum by cross-linked polyvinylpyrrolidone. J Infect Dis 1993; 167:1027-1033
37. Chin S, Williams B, Gottlieb P, Margolis-Nunno H, Ben-Hur E, Hamman J, Jin R, Dubovi E, Horowitz B: Virucidal UVC treatment of plasma and factor VIII concentrate: protection of proteins by antioxidants. Blood 1995; 86:4331-4336
38. Wages D, Smith D, Walsh J, Smyers J, Chen C, Moore C, Jue C, Davis K, Metzel P, Corash L, Cimino G, Hei D, Shafer S, Wiesenhahn G, Buchholz DH: Virally inactivated fresh frozen plasma transfusion in normal volunteers. Vox Sang 1998; 74 (Suppl. 1): 1290 [Abstr.]
39. Goubran HA, Burnouf T, Radosevich M: Virucidal heat-treatment of single plasma units: a potential approach for developing countries. Haemophilia 2000; 6:597-604
40. Zeiler T, Riess H, Wittmann G, Hintz G, Zimmerman RM, Müller C, Heuft HG, Huhn D: The effect of methylene blue photo treatment on plasma proteins and in vitro coagulation capability of single-donor fresh frozen plasma. Transfusion 1994; 34:685-689
41. Hornsey VS, Drummond O, Young D, Docherty A, Prowse CV: A potentially improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco-Tronic system. Transfus Med 2001; 11:31-36
42. Hornsey VS, Krailadsiri P, MacDonald S, Seghatchian S, Williamson LM, Prowse CV: Coagulation factor content of cryoprecipitate prepared from methylene blue plus light virus inactivated plasma. Br J Haematol 2000; 109:665-667
43. Aznar JA, Molina R, Montoro JM: Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasma. Transfusion 1999; 39:748-750
44. Leebeek FWG, Schipperus MD, van Vliet HHDM: Coagulation factor levels in solvent-detergent-treated plasma. Transfusion 1999; 39:1150-1151
45. Burnouf T: Value of virus filtration as a method for improving the safety of plasma products. Vox Sang 1996; 70:235-236